| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Meng Wang, Ming Shen, Wenqiang He, Yeping Yang, Wenjuan Liu, Yun Lu, Zengyi Ma, Zhao Ye, Yichao Zhang, Xiaolong Zhao, Bin Lu, Ji Hu, Yun Huang, Xuefei Shou, Yongfei Wang, Hongying Ye, Yiming Li, Shiqi Li, Yao Zhao, Zhaoyun Zhan. The value of an acute octreotide suppression test in predicting short-term efficacy of somatostatin analogues in acromegaly. Endocrine journal. vol 63. issue 9. 2017-03-03. PMID:27432816. |
the value of an acute octreotide suppression test in predicting short-term efficacy of somatostatin analogues in acromegaly. |
2017-03-03 |
2023-08-13 |
Not clear |
| Filippo Maffezzoni, Anna Maria Formenti, Gherardo Mazziotti, Stefano Frara, Andrea Giustin. Current and future medical treatments for patients with acromegaly. Expert opinion on pharmacotherapy. vol 17. issue 12. 2017-02-22. PMID:27352098. |
the therapeutic options for acromegaly include surgery, medical therapies (such as dopamine agonists, somatostatin receptor ligands and the gh receptor antagonist pegvisomant) and radiotherapy. |
2017-02-22 |
2023-08-13 |
Not clear |
| John Rafferty, Hema Nagaraj, Alice P McCloskey, Rawan Huwaitat, Simon Porter, Alyaa Albadr, Garry Lavert. Peptide Therapeutics and the Pharmaceutical Industry: Barriers Encountered Translating from the Laboratory to Patients. Current medicinal chemistry. vol 23. issue 37. 2017-02-08. PMID:27633684. |
peptides are proving effective for a multitude of disease states including: type 2 diabetes (controlled using the licensed glucagon-like peptide-1 receptor liraglutide); irritable bowel syndrome managed with linaclotide (currently at approval stages); acromegaly (treated with octapeptide somatostatin analogues lanreotide and octreotide); selective or broad spectrum microbicidal agents such as the gram-positive selective ptp-7 and antifungal heliomicin; anticancer agents including goserelin used as either adjuvant or monotherapy for prostate and breast cancer, and the first marketed peptide derived vaccine against prostate cancer, sipuleucel-t. research is also focusing on improving the biostability of peptides. |
2017-02-08 |
2023-08-13 |
Not clear |
| Elina Ritvonen, Esa Pitkänen, Atte Karppinen, Satu Vehkavaara, Hande Demir, Anders Paetau, Camilla Schalin-Jäntti, Auli Karh. Impact of AIP and inhibitory G protein alpha 2 proteins on clinical features of sporadic GH-secreting pituitary adenomas. European journal of endocrinology. vol 176. issue 2. 2017-02-06. PMID:27998919. |
in sporadic acromegaly, downregulation of aip protein of the adenomas associates with invasive tumor features and reduced responsiveness to somatostatin analogues. |
2017-02-06 |
2023-08-13 |
Not clear |
| S E Franck, A Muhammad, A J van der Lely, S J C M M Negger. Combined treatment of somatostatin analogues with pegvisomant in acromegaly. Endocrine. vol 52. issue 2. 2017-01-26. PMID:26661938. |
combined treatment of somatostatin analogues with pegvisomant in acromegaly. |
2017-01-26 |
2023-08-13 |
Not clear |
| S E Franck, A Muhammad, A J van der Lely, S J C M M Negger. Combined treatment of somatostatin analogues with pegvisomant in acromegaly. Endocrine. vol 52. issue 2. 2017-01-26. PMID:26661938. |
treatment of acromegaly with monotherapy long-acting somatostatin analogues (la-ssa) as primary treatment or after neurosurgery can only achieve complete normalization of insulin-like growth factor i (igf-i) in roughly 40 % of patients. |
2017-01-26 |
2023-08-13 |
Not clear |
| Ansgar Heck, Kyrre E Emblem, Olivera Casar-Borota, Jens Bollerslev, Geir Ringsta. Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly. Endocrine. vol 52. issue 2. 2017-01-26. PMID:26475495. |
quantitative analyses of t2-weighted mri as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly. |
2017-01-26 |
2023-08-13 |
Not clear |
| Annamaria Colao, Renata S Auriemma, Rosario Pivonell. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly. Pituitary. vol 19. issue 2. 2016-12-23. PMID:26290466. |
the effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly. |
2016-12-23 |
2023-08-13 |
Not clear |
| Annamaria Colao, Renata S Auriemma, Rosario Pivonell. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly. Pituitary. vol 19. issue 2. 2016-12-23. PMID:26290466. |
somatostatin analogues are the medical treatment of choice in acromegaly, as first-line or post-surgical therapy, and have proven efficacy in pituitary tumor volume reduction (tvr). |
2016-12-23 |
2023-08-13 |
Not clear |
| Philippe Chanso. Medical Treatment of Acromegaly with Dopamine Agonists or Somatostatin Analogs. Neuroendocrinology. vol 103. issue 1. 2016-11-09. PMID:25677539. |
medical treatment of acromegaly with dopamine agonists or somatostatin analogs. |
2016-11-09 |
2023-08-13 |
Not clear |
| Sebastian J C M M Neggers, Ammar Muhammad, Aart Jan van der Lel. Pegvisomant Treatment in Acromegaly. Neuroendocrinology. vol 103. issue 1. 2016-11-09. PMID:25792221. |
somatostatin analogues have become the cornerstones of medical treatment in acromegaly and are even seen as a primary treatment in a selected group of acromegaly patients. |
2016-11-09 |
2023-08-13 |
Not clear |
| Yutaka Ok. Medical management of functioning pituitary adenoma: an update. Neurologia medico-chirurgica. vol 54. issue 12. 2016-11-02. PMID:25446388. |
in patients with acromegaly, dopamine agonists, somatostatin analogues, and growth hormone receptor antagonist have been used as a monotherapy or the combination, and the high remission rate can be achieved. |
2016-11-02 |
2023-08-13 |
Not clear |
| Marcello D Bronstein, Maria Fleseriu, Sebastian Neggers, Annamaria Colao, Michael Sheppard, Feng Gu, Chiung-Chyi Shen, Mônica Gadelha, Andrew J Farrall, Karina Hermosillo Reséndiz, Matthieu Ruffin, YinMiao Chen, Pamela Fred. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study. BMC endocrine disorders. vol 16. 2016-10-19. PMID:27039081. |
many patients with acromegaly do not achieve biochemical control with first-generation somatostatin analogues. |
2016-10-19 |
2023-08-13 |
Not clear |
| Luis Margusino-Framiñán, Sonia Pertega-Diaz, Lara Pena-Bello, Susana Sangiao-Alvarellos, Elena Outeiriño-Blanco, Francisco Pita-Gutierrez, Salvador Pita-Fernandez, Fernando Cordid. Cost-effectiveness analysis of preoperative treatment of acromegaly with somatostatin analogue on surgical outcome. European journal of internal medicine. vol 26. issue 9. 2016-09-12. PMID:26300269. |
cost-effectiveness analysis of preoperative treatment of acromegaly with somatostatin analogue on surgical outcome. |
2016-09-12 |
2023-08-13 |
Not clear |
| Cecilia Follin, Sven Karlsso. Attitudes and preferences in patients with acromegaly on long-term treatment with somatostatin analogues. Endocrine connections. vol 5. issue 4. 2016-08-23. PMID:27458240. |
attitudes and preferences in patients with acromegaly on long-term treatment with somatostatin analogues. |
2016-08-23 |
2023-08-13 |
Not clear |
| Federico Gatto, Nienke R Biermasz, Richard A Feelders, Johan M Kros, Fadime Dogan, Aart-Jan van der Lely, Sebastian J C M M Neggers, Steven W J Lamberts, Alberto M Pereira, Diego Ferone, Leo J Hoflan. Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly. European journal of endocrinology. vol 174. issue 5. 2016-08-09. PMID:26888629. |
low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly. |
2016-08-09 |
2023-08-13 |
Not clear |
| Federico Gatto, Nienke R Biermasz, Richard A Feelders, Johan M Kros, Fadime Dogan, Aart-Jan van der Lely, Sebastian J C M M Neggers, Steven W J Lamberts, Alberto M Pereira, Diego Ferone, Leo J Hoflan. Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly. European journal of endocrinology. vol 174. issue 5. 2016-08-09. PMID:26888629. |
the high expression of somatostatin receptor subtype 2 (sstr2 also known as sst2) usually present in growth hormone (gh)-secreting adenomas is the rationale for therapy with somatostatin analogs (ssas) in acromegaly. |
2016-08-09 |
2023-08-13 |
Not clear |
| A Muhammad, A J van der Lely, R D O'Connor, P J Delhanty, J Dal, A H Dallenga, R A Feelders, J A M J L Janssen, J O L Jorgensen, S J C M M Negger. What is the efficacy of switching to weekly pegvisomant in acromegaly patients well controlled on combination therapy? European journal of endocrinology. vol 174. issue 5. 2016-08-09. PMID:26903550. |
although combination therapy of acromegaly with long-acting somatostatin analogs (la-ssas) and pegvisomant (pegv) normalizes insulin-like growth factor-1 (igf1) levels in the majority of patients, it requires long-term adherence. |
2016-08-09 |
2023-08-13 |
Not clear |
| Michael H Shanik, Paul D Cao, William H Ludla. HISTORICAL RESPONSE RATES OF SOMATOSTATIN ANALOGUES IN THE TREATMENT OF ACROMEGALY: A SYSTEMATIC REVIEW. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. vol 22. issue 3. 2016-08-08. PMID:26437217. |
historical response rates of somatostatin analogues in the treatment of acromegaly: a systematic review. |
2016-08-08 |
2023-08-13 |
Not clear |
| Piero Feroll. Medical Therapy of Pulmonary Neuroendocrine Neoplasms: Targeted, Symptomatic and Chemotherapy. Frontiers of hormone research. vol 44. 2016-06-20. PMID:26303713. |
somatostatin analogs represent the therapy of choice in the presence of associated carcinoid syndrome and ectopic acromegaly and a reasonable first-line in slow-progressing tumors. |
2016-06-20 |
2023-08-13 |
Not clear |